{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:07:33Z","timestamp":1780600053807,"version":"3.54.1"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.lungcan.2017.10.013","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T19:45:54Z","timestamp":1510170354000},"page":"96-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib"],"prefix":"10.1016","volume":"116","author":[{"given":"Yao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baisong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.lungcan.2017.10.013_bib0005","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/bjc.2013.130","article-title":"Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma","volume":"108","author":"Mezzapelle","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"7315","key":"10.1016\/j.lungcan.2017.10.013_bib0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.lungcan.2017.10.013_bib0015","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"33","key":"10.1016\/j.lungcan.2017.10.013_bib0020","doi-asserted-by":"crossref","first-page":"14903","DOI":"10.1073\/pnas.1008990107","article-title":"The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner","volume":"107","author":"Joseph","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.lungcan.2017.10.013_bib0025","first-page":"906","article-title":"FDA approves vemurafenib for treatment of metastatic melanoma","volume":"25","year":"2011","journal-title":"Oncology (Williston Park)"},{"issue":"8","key":"10.1016\/j.lungcan.2017.10.013_bib0030","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2017.10.013_bib0035","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1089\/thy.2013.0057","article-title":"Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation","volume":"23","author":"Kim","year":"2013","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.lungcan.2017.10.013_bib0040","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s10637-015-0297-4","article-title":"Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation","volume":"33","author":"Combe","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.lungcan.2017.10.013_bib0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2017.10.013_bib0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2017.10.013_bib0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21037\/atm.2016.06.07","article-title":"Resistant mechanisms to BRAF inhibitors in melanoma","volume":"4","author":"Manzano","year":"2016","journal-title":"Ann. Transl. Med."},{"issue":"23","key":"10.1016\/j.lungcan.2017.10.013_bib0060","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMc1010755","article-title":"Inhibition of mutated BRAF in melanoma","volume":"363","author":"Kim","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.lungcan.2017.10.013_bib0065","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217305524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217305524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T17:44:52Z","timestamp":1538588692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217305524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":13,"alternative-id":["S0169500217305524"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.10.013","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}